We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Tavalisse Drive Rigel's Growth Through the Rest of 2025?
Read MoreHide Full Article
Key Takeaways
Tavalisse recorded $68.5M in H1 sales, up 44% year over year on strong new patient demand.
Rigel raised the 2025 revenue forecast to $270-$280M, up from the prior guidance of $200-$210M.
Rigel's other marketed products, Rezlidhia and Gavreto, also saw sales increases in H1 2025.
Rigel Pharmaceuticals’ (RIGL - Free Report) first product, Tavalisse (fostamatinib disodium hexahydrate), has been driving the majority of the company’s revenues. The drug remains a key top-line driver for the company.
Tavalisse, an oral spleen tyrosine kinase (SYK) inhibitor, is approved by the FDA for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. The drug is also approved in Europe, the United Kingdom, Japan and some other countries.
In the first half of 2025, Tavalisse generated sales of $68.5 million, up around 44% year over year. Per management, sales of the drug are being driven by continued strong new patient demand and the momentum is expected to continue in the second half of 2025.
Looking ahead, sales are expected to grow steadily as Rigel expands its commercial footprint and strengthens its marketing infrastructure, driving continued momentum for Tavalisse.
Besides Tavalisse, Rigel is also making good progress with its other marketed products, Rezlidhia (olutasidenib) and Gavreto (pralsetinib), which are approved for treating certain cancer indications. Sales of both drugs increased during the first half of 2025.
Rigel has an exclusive license agreement with Dr. Reddy's (RDY - Free Report) to develop and commercialize Rezlidhia in all potential indications throughout Dr. Reddy's territory, which includes Latin America, South Africa, India, Southeast Asia, North Africa, Australia and New Zealand, among others.
Rigel is entitled to receive potential regulatory and commercial milestone payments from RDY.
RIGL Ups Revenue Outlook Amid Rising Competition for Tavalisse
The company increased its total revenue guidance on the second-quarter earnings call last month. Rigel now projects total revenues of $270-$280 million for 2025, compared with the previous expectation of $200-$210 million.
Net product sales are now expected to be in the range of $210-$220 million versus the previous guidance of $185 to $192 million. Tavalisse is expected to remain a meaningful contributor, while competition increases in the ITP market.
Per SNY, Wayrilz is now the first BTK inhibitor to be approved by the FDA for treating ITP in the United States. Wayrilz is currently under review in the EU and China as a treatment for ITP.
Though Tavalisse and Wayrilz are built on different mechanisms, a successful launch of the latter is likely to pose a significant threat to Tavalisse, given the resources available for a large drugmaker like Sanofi.
RIGL’s Price Performance, Valuation and Estimates
Year to date, shares of Rigel have rallied 116.9% compared with the industry’s rise of 12.9%. The stock has also outperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Rigel is trading at a discount to the industry. Going by the price-to-sales (P/S) ratio, the company’s shares currently trade at 2.47, lower than 2.48 for the industry. The stock is trading above its five-year mean of 2.22.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings per share (EPS) has increased from $2.25 to $5.10 over the past 60 days. During the same time frame, EPS estimates for 2026 have moved up from $1.60 to $3.07.
Image: Bigstock
Can Tavalisse Drive Rigel's Growth Through the Rest of 2025?
Key Takeaways
Rigel Pharmaceuticals’ (RIGL - Free Report) first product, Tavalisse (fostamatinib disodium hexahydrate), has been driving the majority of the company’s revenues. The drug remains a key top-line driver for the company.
Tavalisse, an oral spleen tyrosine kinase (SYK) inhibitor, is approved by the FDA for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. The drug is also approved in Europe, the United Kingdom, Japan and some other countries.
In the first half of 2025, Tavalisse generated sales of $68.5 million, up around 44% year over year. Per management, sales of the drug are being driven by continued strong new patient demand and the momentum is expected to continue in the second half of 2025.
Looking ahead, sales are expected to grow steadily as Rigel expands its commercial footprint and strengthens its marketing infrastructure, driving continued momentum for Tavalisse.
Besides Tavalisse, Rigel is also making good progress with its other marketed products, Rezlidhia (olutasidenib) and Gavreto (pralsetinib), which are approved for treating certain cancer indications. Sales of both drugs increased during the first half of 2025.
Rigel has an exclusive license agreement with Dr. Reddy's (RDY - Free Report) to develop and commercialize Rezlidhia in all potential indications throughout Dr. Reddy's territory, which includes Latin America, South Africa, India, Southeast Asia, North Africa, Australia and New Zealand, among others.
Rigel is entitled to receive potential regulatory and commercial milestone payments from RDY.
RIGL Ups Revenue Outlook Amid Rising Competition for Tavalisse
The company increased its total revenue guidance on the second-quarter earnings call last month. Rigel now projects total revenues of $270-$280 million for 2025, compared with the previous expectation of $200-$210 million.
Net product sales are now expected to be in the range of $210-$220 million versus the previous guidance of $185 to $192 million. Tavalisse is expected to remain a meaningful contributor, while competition increases in the ITP market.
The FDA recently approved Sanofi’s (SNY - Free Report) Wayrilz (rilzabrutinib), a novel BTK inhibitor, for the treatment of persistent or chronic ITP in adult patients who have had an insufficient response to a previous treatment.
Per SNY, Wayrilz is now the first BTK inhibitor to be approved by the FDA for treating ITP in the United States. Wayrilz is currently under review in the EU and China as a treatment for ITP.
Though Tavalisse and Wayrilz are built on different mechanisms, a successful launch of the latter is likely to pose a significant threat to Tavalisse, given the resources available for a large drugmaker like Sanofi.
RIGL’s Price Performance, Valuation and Estimates
Year to date, shares of Rigel have rallied 116.9% compared with the industry’s rise of 12.9%. The stock has also outperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Rigel is trading at a discount to the industry. Going by the price-to-sales (P/S) ratio, the company’s shares currently trade at 2.47, lower than 2.48 for the industry. The stock is trading above its five-year mean of 2.22.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings per share (EPS) has increased from $2.25 to $5.10 over the past 60 days. During the same time frame, EPS estimates for 2026 have moved up from $1.60 to $3.07.
Image Source: Zacks Investment Research
RIGL’s Zacks Rank
Rigel currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.